STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of EUR0.11 per share
March 08, 2018 at 03:20 am EST
Share
DGAP-Ad-hoc: STADA Arzneimittel AG / Key word(s): Dividend
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of EUR0.11 per share
08-March-2018 / 09:16 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
March 8, 2018, 8.27 a.m.
Bad Vilbel, March 8, 2018 - The Executive Board and Supervisory Board of STADA Arzneimittel AG (STADA) resolved today to propose to the General Meeting of STADA on June 6, 2018 the payment of a dividend in the amount of EUR0.11 per STADA share and to carry forward the remaining profits in the amount of EUR54m to new account. Thus, the dividend will be significantly lower than in previous years. In order to withstand the competition in the pharmaceuticals market, STADA must be able to invest in R&D, new products, technologies and markets. Therefore, the Executive Board and Supervisory Board consider it necessary to strengthen the company's equity capital. The Executive Board expressly points out that the proposed appropriation of profits is subject to approval by the General Meeting.
As planned, STADA will today, on March 8, 2018 publish its annual financial statements as well as the consolidated annual financial statements for the 2017 financial year.
08-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone:
+49 (0)6101 603- 113
Fax:
+49 (0)6101 603- 506
E-mail:
communications@stada.de
Internet:
www.stada.de
ISIN:
DE0007251803, DE0007251845,
WKN:
725180, 725184,
Indices:
MDAX
Listed:
Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
STADA Arzneimittel AG (STADA) is a global pharmaceutical company that focuses on multisource products. It focuses on three core business segments: Generics offers drugs in the multisource product category, made from readily available, off-patent active ingredients; Brand-Name Products focuses on multisource products that are accessible without active ingredient research and are principally offered to the public in the non-prescription and self-medication product sectors, while Special Pharmaceuticals focuses on products with specific market entry barriers or specialized sales structures, including oncological drugs. STADA generics are sold by numerous subsidiaries in the respective national markets.
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of EUR0.11 per share
STADA ARZNEIMITTEL 
